Table 4.
Atezolizumab and bevacizumab treatment-related adverse events stratified by BMI
| All patients (n = 191) | BMI < 25 (n = 97) | BMI 25+ (n = 94) | p value | |
|---|---|---|---|---|
| Any grade trAEs | 127 (66.5) | 62 (63.9) | 65 (69.2) | 0.44 |
| Grade ≥ 3a trAEs | 39 (20.4) | 21 (21.7) | 18 (19.2) | 0.67 |
| Atezolizumab-related | 15 (7.9) | 11 (11.3) | 4 (4.3) | 0.07 |
| Bevacizumab-related | 26 (13.6) | 12 (12.4) | 14 (14.9) | 0.61 |
| trAEs requiring drug discontinuation | 12 (6.3) | 5 (5.2) | 7 (7.4) | 0.51 |
| Atezolizumab trAEs | ||||
| Overall | 83 (43.5) | 42 (43.3) | 41 (43.6) | 0.96 |
| Fatigue | 31 (16.2) | 10 (10.3) | 21 (22.3) | 0.02 |
| Hepatotoxicity | 28 (14.7) | 16 (16.5) | 12 (12.8) | 0.47 |
| Skin toxicity | 9 (4.7) | 3 (3.1) | 6 (6.4) | 0.28 |
| Colitis | 24 (12.6) | 12 (12.4) | 12 (12.8) | 0.93 |
| Thyroid dysfunction | 9 (4.7) | 8 (8.3) | 1 (1.1) | 0.02 |
| Pneumonitis | 4 (2.1) | 1 (1.0) | 3 (3.2) | 0.30 |
| Bevacizumab trAEs | ||||
| Overall | 83 (43.5) | 40 (41.2) | 43 (45.7) | 0.53 |
| Bleeding | 20 (10.5) | 10 (10.3) | 10 (10.6) | 0.94 |
| Hypertension | 44 (23.0) | 23 (23.7) | 21 (22.3) | 0.82 |
| Proteinuria | 38 (19.9) | 23 (23.7) | 15 (16.0) | 0.18 |
| Thrombosis | 10 (5.2) | 2 (2.1) | 8 (8.5) | 0.045 |
agraded as per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)
trAE treatment-related adverse event